Table 3

Multivariate regression results for incidence of severe immune-related adverse event

EstimateSEStatisticP valueOROR SE
Patient characteristics
 Male gender0.070.090.760.451.070.15
 Charlson Comorbidity Index (excluding cancer)
Immune checkpoint inhibitor use
 CTLA-4 therapy0.290.21.420.161.340.2
 Combination ICI therapy0.890.146.18<0.0012.440.11
Underlying conditions
 Other cancer−0.690.16−4.29<0.0010.50.03
 Renal cell carcinoma−0.350.16−
Regional information
 Zip code average income (normalized)
 Zip code average unemployment (normalized)−0.020.05−0.390.70.980.16
 East South Central−0.250.3−0.830.410.780.02
 New England0.350.211.710.091.420.34
 South Atlantic−0.180.15−
 West North Central0.230.240.960.341.260.12
 West South Central−0.040.17−0.230.820.960.14
  • Note: reference group is female patients on programmed cell death protein 1 or programmed death-ligand 1 therapy with lung cancer in East North Central Region.

  • Other cancers include: bladder cancer, colon cancer, head and neck squamous cell carcinoma Hodgkin’s lymphoma, gastric cancer, liver cancer, cervical cancer, and Merkel cell carcinoma.

  • CTLA-4, cytotoxic T lymphocyte-associated 4; ICI, immune checkpoint inhibitor .